Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
Clinical Genitourinary Cancer|December 3, 2014
Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinomaGuru Sonpavde, Gregory R Pond, Jonathan E Rosenberg, et al.
Nature Communications|August 26, 2022
The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinomaDaniel J Renouf, Jonathan M Loree, Jennifer J Knox, et al.
BJU International|November 14, 2013
A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinomaGregory R Pond, Neeraj Agarwal, Joaquim Bellmunt, et al.
Clinical and Translational Medicine|May 1, 2021
Copy number and transcriptome alterations associated with metastatic lesion response to treatment in colorectal cancerKaren Gambaro, Maud Marques, Suzan McNamara, et al.
Nature Communications|March 7, 2026
DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarcinomaDaniel J Renouf, James T Topham, Jonathan M Loree, et al.
European Urology|December 5, 2012
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trialsGuru Sonpavde, Gregory R Pond, Ronan Fougeray, et al.
Clinical Genitourinary Cancer|November 14, 2013
Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinomaNeeraj Agarwal, Joaquim Bellmunt, Benjamin L Maughan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 26, 2026
Clinical and molecular correlates of circulating tumor fraction in patients with metastatic pancreatic ductal adenocarcinomaJames T Topham, Haley M Beckmann, Joanna M Karasinska, et al.
Hepatology (Baltimore, Md.)|May 19, 2025
Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable hepatocellular carcinoma: HIMALAYA phase 3 randomized clinical trialGeorge Lau, Bruno Sangro, Ann-Lii Cheng, et al.
Pageof 7